Click here to get full coverage on EDGAR Filing Documents for 0001193125-26-302608 - SEC.gov

EDGAR Filing Documents for 0001193125-26-302608  SEC.gov

EDGAR Filing Documents for 0001193125-26-302608 - SEC.gov

Click here to get full coverage on Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story - simplywall.st

Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story  simplywall.st

Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story - simplywall.st

Click here to get full coverage on Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Yahoo Finance Singapore

Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet  Yahoo Finance Singapore

Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Yahoo Finance Singapore

Click here to get full coverage on SNDX: Multiple late-stage and next-gen assets drive growth, with pivotal data expected in 2024–2027 - TradingView

SNDX: Multiple late-stage and next-gen assets drive growth, with pivotal data expected in 2024–2027  TradingView

SNDX: Multiple late-stage and next-gen assets drive growth, with pivotal data expected in 2024–2027 - TradingView

Click here to get full coverage on A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX) - Seeking Alpha

A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX)  Seeking Alpha

A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX) - Seeking Alpha

Click here to get full coverage on TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating - Moomoo

TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating  Moomoo

TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating - Moomoo

Click here to get full coverage on Syndax Adds Two Pipeline Assets for Lung Cancer and Myelofibrosis - Stock Titan

Syndax Adds Two Pipeline Assets for Lung Cancer and Myelofibrosis  Stock Titan

Syndax Adds Two Pipeline Assets for Lung Cancer and Myelofibrosis - Stock Titan

Click here to get full coverage on Syndax Pharmaceuticals unveils new pipeline candidates - BioWorld News

Syndax Pharmaceuticals unveils new pipeline candidates  BioWorld News

Syndax Pharmaceuticals unveils new pipeline candidates - BioWorld News

Click here to get full coverage on SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus

SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40  GuruFocus

SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus

Click here to get full coverage on SNDX Stock Price, Quote & Chart - ChartMill

SNDX Stock Price, Quote & Chart  ChartMill

SNDX Stock Price, Quote & Chart - ChartMill

Click here to get full coverage on Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies - Slideshow (NASDAQ:SNDX) 2026-07-14 - Seeking Alpha

Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies - Slideshow (NASDAQ:SNDX) 2026-07-14  Seeking Alpha

Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies - Slideshow (NASDAQ:SNDX) 2026-07-14 - Seeking Alpha

Click here to get full coverage on SNDX: Multiple late-stage and novel assets drive growth, with key data readouts expected in 2024–2025 - TradingView

SNDX: Multiple late-stage and novel assets drive growth, with key data readouts expected in 2024–2025  TradingView

SNDX: Multiple late-stage and novel assets drive growth, with key data readouts expected in 2024–2025 - TradingView

Click here to get full coverage on Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates? - Yahoo Finance

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?  Yahoo Finance

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates? - Yahoo Finance

Click here to get full coverage on Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts - Stock Titan

Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts  Stock Titan

Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts - Stock Titan

Click here to get full coverage on SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027 - TradingView

SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027  TradingView

SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027 - TradingView

Click here to get full coverage on SNDX: Multiple late-stage assets and near-term catalysts drive growth and value creation - TradingView

SNDX: Multiple late-stage assets and near-term catalysts drive growth and value creation  TradingView

SNDX: Multiple late-stage assets and near-term catalysts drive growth and value creation - TradingView

Click here to get full coverage on Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness - Yahoo Finance

Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness  Yahoo Finance

Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness - Yahoo Finance

Click here to get full coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright  MarketBeat

Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Click here to get full coverage on Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail

Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX)  The Globe and Mail

Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail

Click here to get full coverage on SNDX Forecast — Price Target — Prediction for 2027 - TradingView

SNDX Forecast — Price Target — Prediction for 2027  TradingView

SNDX Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - GlobeNewswire

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event  GlobeNewswire

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - GlobeNewswire

Click here to get full coverage on Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates  Yahoo Finance

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential - Yahoo Finance

Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential  Yahoo Finance

Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential - Yahoo Finance

Click here to get full coverage on Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next - simplywall.st

Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next  simplywall.st

Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next - simplywall.st

Click here to get full coverage on Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In? - simplywall.st

Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In?  simplywall.st

Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In? - simplywall.st

Click here to get full coverage on Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting? - Yahoo Finance

Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?  Yahoo Finance

Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting? - Yahoo Finance

Click here to get full coverage on Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed - Yahoo Finance

Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed  Yahoo Finance

Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed - Yahoo Finance

Click here to get full coverage on SNDX insider files to sell 32,375 shares (NASDAQ: SNDX) - Stock Titan

SNDX insider files to sell 32,375 shares (NASDAQ: SNDX)  Stock Titan

SNDX insider files to sell 32,375 shares (NASDAQ: SNDX) - Stock Titan

Click here to get full coverage on H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy - Investing.com

H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy  Investing.com

H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy - Investing.com

Click here to get full coverage on Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan

Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan  Stock Titan

Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan

Click here to get full coverage on Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation - Yahoo Finance

Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation  Yahoo Finance

Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation - Yahoo Finance

Click here to get full coverage on Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX) - Seeking Alpha

Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX)  Seeking Alpha

Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX) - Seeking Alpha

Click here to get full coverage on Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance

Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story?  Yahoo Finance

Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance

Click here to get full coverage on Cancer drug sales top $100M as Syndax lines up late-2026 trial data - Stock Titan

Cancer drug sales top $100M as Syndax lines up late-2026 trial data  Stock Titan

Cancer drug sales top $100M as Syndax lines up late-2026 trial data - Stock Titan

Click here to get full coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares - MarketBeat

Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares  MarketBeat

Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares - MarketBeat

Click here to get full coverage on Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily

Technical Reactions to SNDX Trends in Macro Strategies  Stock Traders Daily

Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily

Click here to get full coverage on Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  Yahoo Finance

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance

Click here to get full coverage on Syndax Pharmaceuticals Inc ($SNDX) CEO 2025 Pay Revealed - Quiver Quantitative

Syndax Pharmaceuticals Inc ($SNDX) CEO 2025 Pay Revealed  Quiver Quantitative

Syndax Pharmaceuticals Inc ($SNDX) CEO 2025 Pay Revealed - Quiver Quantitative

Click here to get full coverage on Syndax lines up $250M in 2.25% debt swappable into its stock - Stock Titan

Syndax lines up $250M in 2.25% debt swappable into its stock  Stock Titan

Syndax lines up $250M in 2.25% debt swappable into its stock - Stock Titan

Click here to get full coverage on Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - simplywall.st

Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives  simplywall.st

Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - simplywall.st

Click here to get full coverage on Inside Syndax’s next cancer R&D day: leukemia and lung disease trials - Stock Titan

Inside Syndax’s next cancer R&D day: leukemia and lung disease trials  Stock Titan

Inside Syndax’s next cancer R&D day: leukemia and lung disease trials - Stock Titan

Click here to get full coverage on Trading the Move, Not the Narrative: (SNDX) Edition - Stock Traders Daily

Trading the Move, Not the Narrative: (SNDX) Edition  Stock Traders Daily

Trading the Move, Not the Narrative: (SNDX) Edition - Stock Traders Daily

Click here to get full coverage on Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX) - Seeking Alpha

Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX)  Seeking Alpha

Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX) - Seeking Alpha

Click here to get full coverage on SNDX: Compelling clinical results and commercial momentum position both franchises for significant growth - TradingView

SNDX: Compelling clinical results and commercial momentum position both franchises for significant growth  TradingView

SNDX: Compelling clinical results and commercial momentum position both franchises for significant growth - TradingView

Click here to get full coverage on (SNDX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

(SNDX) Price Dynamics and Execution-Aware Positioning  Stock Traders Daily

(SNDX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Click here to get full coverage on Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Benchmark - marketscreener.com

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Benchmark  marketscreener.com

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Benchmark - marketscreener.com

Click here to get full coverage on Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options - Stock Titan

Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options  Stock Titan

Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options - Stock Titan

Click here to get full coverage on Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year  simplywall.st

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st

Click here to get full coverage on Syndax’s Third FDA Win Accelerates Shift To Multi Product Revenues - simplywall.st

Syndax’s Third FDA Win Accelerates Shift To Multi Product Revenues  simplywall.st

Syndax’s Third FDA Win Accelerates Shift To Multi Product Revenues - simplywall.st

Click here to get full coverage on SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX  MarketBeat

SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Click here to get full coverage on [144] Syndax Pharmaceuticals Inc SEC Filing - Stock Titan

[144] Syndax Pharmaceuticals Inc SEC Filing  Stock Titan

[144] Syndax Pharmaceuticals Inc SEC Filing - Stock Titan

Click here to get full coverage on Guggenheim Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $31 - Moomoo

Guggenheim Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $31  Moomoo

Guggenheim Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $31 - Moomoo

Click here to get full coverage on SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval - Stocktwits

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval  Stocktwits

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval - Stocktwits

Click here to get full coverage on Syndax Pharmaceuticals to Announce Q1 2026 Financial Results and Business Update on April 30, 2026 - Quiver Quantitative

Syndax Pharmaceuticals to Announce Q1 2026 Financial Results and Business Update on April 30, 2026  Quiver Quantitative

Syndax Pharmaceuticals to Announce Q1 2026 Financial Results and Business Update on April 30, 2026 - Quiver Quantitative

Click here to get full coverage on Syndax Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance

Syndax Pharmaceuticals Q4 Earnings Call Highlights  Yahoo Finance

Syndax Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance

Click here to get full coverage on 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - 24/7 Wall St.

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal  24/7 Wall St.

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - 24/7 Wall St.

Click here to get full coverage on Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031 - Stock Titan

Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031  Stock Titan

Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031 - Stock Titan

Click here to get full coverage on Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX) - Seeking Alpha

Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX)  Seeking Alpha

Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX) - Seeking Alpha

Click here to get full coverage on Price-Driven Insight from (SNDX) for Rule-Based Strategy - Stock Traders Daily

Price-Driven Insight from (SNDX) for Rule-Based Strategy  Stock Traders Daily

Price-Driven Insight from (SNDX) for Rule-Based Strategy - Stock Traders Daily

Click here to get full coverage on Syndax Pharmaceuticals (SNDX) Edges Lower as Shares Test Key Support Levels - Synthetic Long - dars.gov.et

Syndax Pharmaceuticals (SNDX) Edges Lower as Shares Test Key Support Levels - Synthetic Long  dars.gov.et

Syndax Pharmaceuticals (SNDX) Edges Lower as Shares Test Key Support Levels - Synthetic Long - dars.gov.et

Click here to get full coverage on Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Finviz

Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs  Finviz

Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Finviz

Click here to get full coverage on Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 - GlobeNewswire

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026  GlobeNewswire

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 - GlobeNewswire

Click here to get full coverage on Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo

Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing  Moomoo

Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo

Click here to get full coverage on Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes - GlobeNewswire

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes  GlobeNewswire

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes - GlobeNewswire

Click here to get full coverage on Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highligh - GuruFocus

Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highligh  GuruFocus

Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highligh - GuruFocus

Click here to get full coverage on Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology - GlobeNewswire

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology  GlobeNewswire

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology - GlobeNewswire

Click here to get full coverage on Have Insiders Sold Syndax Pharmaceuticals Shares Recently? - simplywall.st

Have Insiders Sold Syndax Pharmaceuticals Shares Recently?  simplywall.st

SNDX

Price Chart

Key Statistics

Technicals

About SNDX

Latest News

EDGAR Filing Documents for 0001193125-26-302608 - SEC.gov

Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story - simplywall.st

Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Yahoo Finance Singapore

Advanced Charts

Top Gainers

Top Losers